BlogTalkRadio uses cookies. By using our services, you're agreeing to our Cookies Policy. Got it

Our Terms of Use and Privacy Policy have changed. We think you'll like them better this way.

Balancing Benefit and Toxicity from Immunotherapeutics

  • Broadcast in Science
Pharma Talk Radio

Pharma Talk Radio

×  

Follow This Show

If you liked this show, you should follow Pharma Talk Radio.
h:548881
s:11100141
archived

Jeffrey Weber, Deputy Director at Laura and Isaac Perlmutter Cancer Center and Co-director of Melanoma Program and Head of Experimental Therapeutics at NYU Langone Medical Center, discusses the day to day management of, and the science around, IO adverse events that may help us understand how these drugs work. Including:

  • The need to educate physicians about management of immune related adverse events with increasing penetration of checkpoint inhibitors into the community
  • The relationship of these adverse events to outcome with checkpoint inhibition
  • The relation of adverse events to other autoimmune diseases that are similar in nature

This session was presented at the 4th annual Immuno-Oncology 360 conference in February 2018.

For more information on the IO360 conference and details for the 5th annual program taking place February 6-8, 2019 in New York, NY, please visit io360summit.com

Comments